Hans Geinitz1,2, Reinhard Thamm3, Christian Scholz3, Christine Heinrich3, Nina Prause3, Simone Kerndl3, Monika Keller4, Raymonde Busch5, Michael Molls3, Frank B Zimmermann3. 1. Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany. hans.geinitz@lrz.tu-muenchen.de. 2. Klinik und Poliklinik für Strahlentherapie und Radiologische Onkologie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Straße 22, 81675, München, Germany. hans.geinitz@lrz.tu-muenchen.de. 3. Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany. 4. Psychooncology Section, Department of Psychosomatic and General Clinical Medicine, University Hospital, Heidelberg, Germany. 5. Institute of Medical Statistics and Epidemiology, Technische Universität München, München, Germany.
Abstract
PURPOSE: To prospectively assess quality of life (QoL) in patients receiving conformal radiation therapy (CRT) for prostate cancer. PATIENTS AND METHODS: 78 men with definitive CRT for prostate cancer were entered into the study. Patients were assessed before CRT, at 40 and 60 Gy, and 2, 12 and 24 months after the end of treatment. QoL was assessed using the EORTC Quality of Life Questionnaire C30 and the prostate module PR25. Changes in mean QoL scores with time of >or= 10 points were considered clinically relevant. RESULTS: Global QoL did not change statistically significant during CRT and was slightly above baseline levels during follow-up. CRT had a statistically significant negative short-term impact on role functioning, fatigue, and PR25 urinary symptoms. The scores recovered within 2 months to 1 year after CRT. Emotional functioning and social functioning scores slightly increased during and after CRT. Role functioning decreased by > 10 points at 60 Gy and urinary symptoms decreased by > 10 points at 40 and 60 Gy. All other differences were < 10 points. A high number of concomitant diseases and having no children were negative pretreatment predictors for long-term global QoL. CONCLUSION: Definitive CRT for prostate cancer does not compromise global QoL during therapy and up to 2 years after treatment. It has a limited negative effect on role functioning, urinary symptoms and, to a lesser extent, on fatigue with restitution within 2 months to 1 year after treatment.
PURPOSE: To prospectively assess quality of life (QoL) in patients receiving conformal radiation therapy (CRT) for prostate cancer. PATIENTS AND METHODS: 78 men with definitive CRT for prostate cancer were entered into the study. Patients were assessed before CRT, at 40 and 60 Gy, and 2, 12 and 24 months after the end of treatment. QoL was assessed using the EORTC Quality of Life Questionnaire C30 and the prostate module PR25. Changes in mean QoL scores with time of >or= 10 points were considered clinically relevant. RESULTS: Global QoL did not change statistically significant during CRT and was slightly above baseline levels during follow-up. CRT had a statistically significant negative short-term impact on role functioning, fatigue, and PR25 urinary symptoms. The scores recovered within 2 months to 1 year after CRT. Emotional functioning and social functioning scores slightly increased during and after CRT. Role functioning decreased by > 10 points at 60 Gy and urinary symptoms decreased by > 10 points at 40 and 60 Gy. All other differences were < 10 points. A high number of concomitant diseases and having no children were negative pretreatment predictors for long-term global QoL. CONCLUSION: Definitive CRT for prostate cancer does not compromise global QoL during therapy and up to 2 years after treatment. It has a limited negative effect on role functioning, urinary symptoms and, to a lesser extent, on fatigue with restitution within 2 months to 1 year after treatment.
Authors: Jane T Hickok; Joseph A Roscoe; Gary R Morrow; Karen Mustian; Paul Okunieff; Christopher W Bole Journal: Cancer Date: 2005-10-15 Impact factor: 6.860
Authors: Jeff A Sloan; Marlene H Frost; Rick Berzon; Amylou Dueck; Gordon Guyatt; Carol Moinpour; Mirjam Sprangers; Carol Ferrans; David Cella Journal: Support Care Cancer Date: 2006-06-23 Impact factor: 3.603
Authors: Hans Geinitz; Frank B Zimmermann; Reinhard Thamm; Andreas Schumertl; Raymonde Busch; Michael Molls Journal: Radiother Oncol Date: 2005-07 Impact factor: 6.280
Authors: Stephanie T H Peeters; Wilma D Heemsbergen; Wim L J van Putten; Annerie Slot; Hans Tabak; Jan Willem Mens; Joos V Lebesque; Peter C M Koper Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Razvan M Galalae; Tillmann Loch; Birgit Riemer; Peter Rzehak; Thomas Küchler; Bernhard Kimmig; György Kovács Journal: Strahlenther Onkol Date: 2004-09 Impact factor: 3.621
Authors: Kimberly E Alexander; Bruce A Cooper; Steven M Paul; Patsy Yates; Bradley E Aouizerat; Christine Miaskowski Journal: Qual Life Res Date: 2016-05-09 Impact factor: 4.147
Authors: Michael Pinkawa; Richard Holy; Marc D Piroth; Karin Fischedick; Sandra Schaar; Dalma Székely-Orbán; Michael J Eble Journal: Radiat Oncol Date: 2010-04-08 Impact factor: 3.481
Authors: Emma B Holliday; Nathan F Dieckmann; Tasha L McDonald; Arthur Y Hung; Charles R Thomas; Lisa J Wood Journal: Radiother Oncol Date: 2015-12-29 Impact factor: 6.280